Home>Topics>Companies>Eli Lilly

Eli Lilly LLY

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Acrux Result As Expected and FDA Ruling Still Pending; We Reduce Fair Value Estimate Slightly

      Commentary

      Thu, 26 Feb 2015

      reflecting the lack of direct control by Acrux over Axiron sales, which is distributed by its giant pharmaceutical partner Eli Lilly . We maintain our very high fair value uncertainty rating given the potential impact of an adverse ruling by the FDA on

    2. UPDATE 1-Lilly long-acting insulin delayed by liver concerns

      Headlines

      Mon, 23 Feb 2015

      Feb 23 (Reuters) - Eli Lilly and Co said it would postpone by at least two years the marketing application for its once-daily diabetes treatment to evaluate liver concerns, a delay some analysts said could doom the experimental drug.

    3. Lilly delays submission to market once-daily diabetes drug

      Headlines

      Mon, 23 Feb 2015

      Feb 23 (Reuters) - Eli Lilly and Co said it would delay its application to market its once-daily diabetes treatment, basal insulin peglispro, beyond the current quarter.

    4. Incyte Reports Another Solid Quarter of Jakafi Growth and Pipeline Progress

      Commentary

      Fri, 13 Feb 2015

      continued to make progress on its pipeline. Baricitinib, the oral treatment for rheumatoid arthritis that is partnered with Eli Lilly , recently reported positive initial top-line results and will be reporting additional data from its Phase III program

    5. Cuban immigrant gets 6 years over Eli Lilly heist in Connecticut

      Headlines

      Wed, 4 Feb 2015

      Feb 4 (Reuters) - A Cuban immigrant who pleaded guilty to having a role in the theft of more than $50 million of pharmaceuticals from an Eli Lilly and Co warehouse in northern Connecticut was sentenced on Wednesday to 6-1/4 years in prison.

    6. UPDATE 1-FDA approves Boehringer-Lilly drug for type-2 diabetes patients

      Headlines

      Mon, 2 Feb 2015

      Feb 2 (Reuters) - The U.S. Food and Drug Administration approved a drug developed by Eli Lilly and Co and Boehringer Ingelheim Pharmaceuticals Inc to improve blood sugar control in type-2 diabetes patients, the companies said.

    7. FDA approves Boehringer-Lilly drug for type-2 diabetes patients

      Headlines

      Mon, 2 Feb 2015

      Feb 2 (Reuters) - The U.S. Food and Drug Administration approved a drug developed by Eli Lilly and Co and privately held Boehringer Ingelheim Pharmaceuticals Inc to improve blood sugar control in type-2 diabetes patients, the companies said.

    8. Acrux's Axiron Maintains Market Share Despite Increasing Generic Competition

      Commentary

      Sun, 1 Feb 2015

      Net sales for Axiron, Acrux's lead product out-licenced to Eli Lilly , for the quarter ended 31 December 2014 totalled USD 47.6 million, up 31% sequentially from USD 36.3 million, but down

    9. UPDATE 1-Drugmaker Lilly cuts revenue forecast as dollar strengthens

      Headlines

      Fri, 30 Jan 2015

      Jan 30 (Reuters) - Eli Lilly and Co cut its 2015 revenue forecast, issued earlier this month, as the U.S. drugmaker expects a bigger hit from a stronger dollar.

    10. Drugmaker Lilly's Q4 profit falls on strong dollar, charge

      Headlines

      Fri, 30 Jan 2015

      Jan 30 (Reuters) - U.S. drugmaker Eli Lilly and Co reported a 41 percent fall in quarterly profit, hurt by a stronger dollar and a one-time charge related to a restructuring program.

    « Prev12345Next »
    Content Partners